×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
NASDAQ:APTX

Aptinyx Stock Forecast, Price & News

$0.45
+0.02 (+5.47%)
(As of 06/24/2022 04:00 PM ET)
Add
Compare
Today's Range
$0.43
$0.47
50-Day Range
$0.38
$1.06
52-Week Range
$0.36
$3.76
Volume
425,300 shs
Average Volume
361,275 shs
Market Capitalization
$30.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.67
30 days | 90 days | 365 days | Advanced Chart

Receive APTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptinyx and its competitors with MarketBeat's FREE daily newsletter.

APTX Stock Forecast (MarketRank)

Overall MarketRank

2.21 out of 5 stars

Medical Sector

368th out of 1,411 stocks

Pharmaceutical Preparations Industry

159th out of 672 stocks

Analyst Opinion: 4.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -
Aptinyx logo

About Aptinyx (NASDAQ:APTX)

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

APTX Stock News Headlines

Expert Ratings for Aptinyx
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APTX
Fax
N/A
Employees
40
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
6/26/2022
Next Earnings (Estimated)
8/09/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$4.67
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+948.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83333333333333
Research Coverage
6 Analysts

Profitability

Net Income
$-74.89 million
Pretax Margin
-7,488.60%

Debt

Sales & Book Value

Annual Sales
$1 million
Book Value
$1.40 per share

Miscellaneous

Free Float
61,026,000
Market Cap
$30.14 million
Optionable
Not Optionable
Beta
1.49














Aptinyx Frequently Asked Questions

Should I buy or sell Aptinyx stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Aptinyx stock.
View analyst ratings for Aptinyx
or view top-rated stocks.

What is Aptinyx's stock price forecast for 2022?

6 analysts have issued 12 month price objectives for Aptinyx's shares. Their APTX stock forecasts range from $2.00 to $6.00. On average, they anticipate Aptinyx's share price to reach $4.67 in the next year. This suggests a possible upside of 948.5% from the stock's current price.
View analysts' price targets for Aptinyx
or view top-rated stocks among Wall Street analysts.

How has Aptinyx's stock performed in 2022?

Aptinyx's stock was trading at $2.67 at the beginning of the year. Since then, APTX stock has decreased by 83.3% and is now trading at $0.4451.
View the best growth stocks for 2022 here
.

When is Aptinyx's next earnings date?

Aptinyx is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Aptinyx
.

How were Aptinyx's earnings last quarter?

Aptinyx Inc. (NASDAQ:APTX) issued its quarterly earnings data on Thursday, May, 12th. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.02. During the same quarter in the previous year, the company earned ($0.22) earnings per share.
View Aptinyx's earnings history
.

Who are Aptinyx's key executives?

Aptinyx's management team includes the following people:
  • Dr. Norbert G. Riedel, Exec. Chairman (Age 64, Pay $851.45k)
  • Dr. Andrew D. Kidd B.M. B.Ch., M.D., CEO, Pres & Director (Age 45, Pay $685.61k)
  • Mr. Ashish Khanna, CFO & Chief Bus. Officer (Age 46, Pay $603.76k) (LinkedIn Profile)
  • Mr. Juan Estupinan, VP of Fin. & Accounting and Controller
  • Mr. Patrick Flavin, Sr. Mang. of Corp. Devel. & Investor Relations
  • Ms. Molly Dir, VP of HR
  • Dr. Kathryn King Ph.D., Sr. VP of Clinical & CMC Operations
  • Dr. Harald Murck M.D., Ph.D., VP of Clinical & Medical Affairs

What other stocks do shareholders of Aptinyx own?

When did Aptinyx IPO?

(APTX) raised $77 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is Aptinyx's stock symbol?

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

Who are Aptinyx's major shareholders?

Aptinyx's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.90%), Frazier Life Sciences Management L.P. (2.78%), BlackRock Inc. (1.94%), DLD Asset Management LP (0.00%), Northern Trust Corp (0.32%) and Silverarc Capital Management LLC (0.00%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Ashish Khanna, Bain Capital Life Sciences Inv, Joan W Miller, Norbert G Riedel, Rachel E Sherman, Robert J Hombach and Robert J Hombach.
View institutional ownership trends for Aptinyx
.

Which institutional investors are selling Aptinyx stock?

APTX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., and Simplex Trading LLC.
View insider buying and selling activity for Aptinyx
or view top insider-selling stocks.

Which institutional investors are buying Aptinyx stock?

APTX stock was purchased by a variety of institutional investors in the last quarter, including Frazier Life Sciences Management L.P., DLD Asset Management LP, Silverarc Capital Management LLC, Vanguard Group Inc., Northern Trust Corp, Victory Capital Management Inc., Assenagon Asset Management S.A., and Cetera Advisor Networks LLC. Company insiders that have bought Aptinyx stock in the last two years include Ashish Khanna, Bain Capital Life Sciences Inv, Joan W Miller, Norbert G Riedel, and Robert J Hombach.
View insider buying and selling activity for Aptinyx
or or view top insider-buying stocks.

How do I buy shares of Aptinyx?

Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aptinyx's stock price today?

One share of APTX stock can currently be purchased for approximately $0.45.

How much money does Aptinyx make?

Aptinyx (NASDAQ:APTX) has a market capitalization of $30.14 million and generates $1 million in revenue each year. The company earns $-74.89 million in net income (profit) each year or ($1.18) on an earnings per share basis.

How many employees does Aptinyx have?

Aptinyx employs 40 workers across the globe.

How can I contact Aptinyx?

Aptinyx's mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The official website for Aptinyx is www.aptinyx.com. The company can be reached via phone at (847) 871-0377 or via email at [email protected].

This page (NASDAQ:APTX) was last updated on 6/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.